Lucence Diagnostics participated in the 4th Annual Liquid Biopsy Summit in San Francisco on June 17-19, 2019, alongside leading researchers from around the world to discuss the latest advances in liquid biopsy.
Our Director of Healthcare Analytics, Dr Jack Challis, spoke on “Illuminating Asian Cancers: Detecting Cancer-Associated Genomic Alterations and Viral DNA Using Liquid Biopsy”. Asia comprises 60% of the world’s population, and half of the new cancer cases worldwide occur in this region.
Dr Challis presented detailed validation data on our proprietary amplicon-based ultra-deep sequencing AmpliMARK™ technology, which enables the accurate detection of somatic mutations in cancers that are common among Asians, such as lung, liver and nasopharyngeal cancers. He also shed light on the current state and future expectations of liquid biopsies in lung cancer.
Improvements in liquid biopsy have allowed it to be used as a clinical swiss-army knife for diverse applications, including cancer screening, diagnosis, monitoring, treatment selection, and resistance detection.
Rapid developments in liquid biopsy will advance the early detection of cancer and bring us closer to a world without avoidable cancer deaths.